Gilead Sciences, Inc. (GILD)
68.88 +0.07 (0.10%)
Before hours: 5:33AM EDT
| Previous close | 69.00 |
| Open | 69.02 |
| Bid | 0.00 x 2200 |
| Ask | 69.47 x 1200 |
| Day's range | 68.62 - 69.61 |
| 52-week range | 60.89 - 85.97 |
| Volume | 7,980,946 |
| Avg. volume | 9,953,084 |
| Market cap | 86.313B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.72 (3.94%) |
| Ex-dividend date | 14 Sep 2020 |
| 1y target est | N/A |
- Business Wire
Diodes Incorporated Reports Second Quarter 2020 Financial Results
Diodes Incorporated (Nasdaq: DIOD) today reported its financial results for the second quarter ended June 30, 2020.
- Reuters
State attorneys general urge U.S. to let other firms make Gilead COVID-19 drug
The coalition of more than 30 state attorneys general called on the government to act or allow states to do so, saying in a letter to U.S. health agencies that Gilead "has not established a reasonable price" for remdesivir. "Gilead should not profit from the pandemic and it should be pushed to do more to help more people," the letter said.
- Motley Fool
Is Gilead Sciences a Buy After Its Disappointing Q2 Results?
Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.
